Payment overview · 2025
General Payments
$13,138.70
29 reported records · 15 companies
Healthcare provider profile · identity verified
Andrew Jared Nagy
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · SAN ANTONIO, TX · NPI 1407242100
Verified facts
What the public records show
CMS Open Payments records show Andrew Jared Nagy received $13,138.70 in general payments during 2025 across 29 reported records.
AngioDynamics, Inc. accounted for 81.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $10,638.89 | 81.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $793.38 | 6.0% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $360.90 | 2.8% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $233.11 | 1.8% | 7 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $164.37 | 1.2% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $161.63 | 1.2% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $157.54 | 1.2% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $152.53 | 1.2% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $149.62 | 1.1% | 1 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $147.74 | 1.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.26 | 0.3% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $41.14 | 0.3% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $40.36 | 0.3% | 2 | 2025 |
| Veloxis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.63 | 0.3% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $21.60 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $10,638.89 | 1 |
| Food and Beverage | $1,899.81 | 27 |
| Consulting Fee | $600.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $10,638.89 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $600.00 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $360.90 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $360.90 | 2 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc., Becton, Dickinson and Company | $193.89 | 5 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Stent Graft Normalized: gore tag conformable thoracic stent graft |
Device | W. L. Gore & Associates, Inc. | $164.37 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $161.63 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $161.63 | 2 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $157.54 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $149.99 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $149.99 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $149.62 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $149.62 | 1 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $147.74 | 1 | 2025 |
Source payment records
|
|||||
| HT Bilevel Pro Core Normalized: ht bilevel pro core |
Device | Philips North America LLC | $43.39 | 2 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $41.14 | 1 | 2025 |
Source payment records
|
|||||
| ENVARSUS Normalized: envarsus |
Drug | Veloxis Pharmaceuticals, Inc. | $33.63 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| Fluency Endovascular Stent Graft Normalized: fluency endovascular stent graft |
Device | Bard Peripheral Vascular, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Progel Applicator Spray Tips Normalized: progel applicator spray tips |
Device | Becton, Dickinson and Company | $13.33 | 1 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Becton, Dickinson and Company | $10.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 63 | 24 |
| Tramadol Hcl | Tramadol Hcl | 62 | 52 |
| Gabapentin | Gabapentin | 33 | 11 |
| Eliquis | Apixaban | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,138.70 · 29 records | AngioDynamics, Inc. | ARTEGRAFT VASCULAR GRAFT, Auryon Laser System 100-120 Vac, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, CGuard Prime Carotid Stent System, CT THROMBECTOMY SYSTEM KIT, Crosser IQ, ENDOCROSS Device, ENVARSUS, FLOWTRIEVER CATHETER, S, Flexitouch Plus, Fluency Endovascular Stent Graft, GORE TAG Conformable Thoracic Stent Graft, General - Vascular Intervention, HT Bilevel Pro Core, IGT Devices Undivided, IMPEDE EMBOLIZATION PLUG, IV Other, Kerecis GraftGuide, Kerecis SurgiClose, LUTONIX Drug Coated Balloon, Nimbl, Progel Applicator Spray Tips, RotarexS 6 F x 135 cm, Torus Stent Graft System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error